MedTrace Logo

A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT06277934 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2025-08-07

No results posted yet for this study

Summary

The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity

Conditions

Interventions

DRUG

RGT001-075

Administered orally

DRUG

Placebo

Administered orally

Sponsors & Collaborators

  • Regor Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-08
Primary Completion
2024-08-13
Completion
2024-08-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06277934 on ClinicalTrials.gov